This submission from Baptist Cancer Institute Community Clinical Oncology Program (BCI-COOP) is a continuation application from a group of investigators and an institution that have just completed their second full year of operation under the NCI's CCOP program. In two short years, the BCI-CCOP has built a strong cadre of 53 investigators with an experienced data management staff. The program has been able to secure supplemental funding commitments from the Baptist Memorial Health Foundation of over 700,000 dollars for the next five-year funding period and has a demonstrated track record of meeting and exceeding NCI requirements. The initial accomplishments of the program include: 52 patients accrued to NCI clinical trials in the 01 Year; 66 patients accrued in the 02 Year; 25 patients accrued to cancer control and prevention trials in the 01 Year; 31 patients accrued in the 02 Year; 21 patients enrolled in the P-1 study in the twelve months this trial was open during the initial funding period; 25 percent of clinical research enrollees from minority populations; 19 percent of cancer control enrollees from minority populations. In addition, one BCI investigator serves as a multi-institutional Study Coordinator on a trial piloted at BCI for the RTOG, while another BCI investigator is Chairman of the GOG CCOP Committee. This type of involvement in our research bases reflects the significant commitment of investigators in both the science and accrual aspects of the CCOP program. Data collection audits for the program have been uniformly high, in one case prompting GOG to ask a BCI Research Nurse to join their Data Management Committee. In the five year term of this application, the BCI plans to expand clinical research accrual to 73 patients using a mixture of clinical trials from five research bases: CALGB, RTOG, NSABP, GOG and MD Anderson. With the advent of the P-2 trial, the BCI expects a significant increase in cancer control and prevention accrual to 60 patients and 60 credits.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA071323-04
Application #
2864848
Study Section
Special Emphasis Panel (ZCA1-SRRB-7 (J4))
Project Start
1996-09-30
Project End
2002-05-31
Budget Start
1999-07-20
Budget End
2000-05-31
Support Year
4
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Baptist Memorial Hospital (Memphis, TN)
Department
Type
DUNS #
City
Memphis
State
TN
Country
United States
Zip Code
38146
Heist, Rebecca S; Wang, Xiaofei; Hodgson, Lydia et al. (2014) CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol 9:214-21
Jeon, Justin; Sato, Kaori; Niedzwiecki, Donna et al. (2013) Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. Clin Colorectal Cancer 12:233-8
Ogino, Shuji; Shima, Kaori; Meyerhardt, Jeffrey A et al. (2012) Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res 18:890-900
Bertagnolli, Monica M; Redston, Mark; Compton, Carolyn C et al. (2011) Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. J Clin Oncol 29:3153-62
Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST) (2010) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 28:1247-53
Ogino, Shuji; Meyerhardt, Jeffrey A; Irahara, Natsumi et al. (2009) KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res 15:7322-9
Bertagnolli, Monica M; Warren, Robert S; Niedzwiecki, Donna et al. (2009) p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803. Clin Cancer Res 15:2116-22
Stinchcombe, Thomas E; Hodgson, Lydia; Herndon 2nd, James E et al. (2009) Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. J Thorac Oncol 4:1117-25
Chan, Jennifer A; Meyerhardt, Jeffrey A; Niedzwiecki, Donna et al. (2008) Association of family history with cancer recurrence and survival among patients with stage III colon cancer. JAMA 299:2515-23
Vokes, Everett E; Herndon 2nd, James E; Kelley, Michael J et al. (2007) Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 25:1698-704

Showing the most recent 10 out of 17 publications